Kullingsjö J - Search Results

1

The dopaminergic stabilizer pridopidine decreases expression of L-DOPA-induced locomotor sensitisation in the rat unilateral 6-OHDA model.

Ponten H, Kullingsjö J, Sonesson C, Waters S, Waters N, Tedroff J. Ponten H, et al. Among authors: kullingsjo j. Eur J Pharmacol. 2013 Jan 5;698(1-3):278-85. doi: 10.1016/j.ejphar.2012.10.039. Epub 2012 Nov 2. Eur J Pharmacol. 2013. PMID: 23127496

2

In vivo pharmacology of the dopaminergic stabilizer pridopidine.

Ponten H, Kullingsjö J, Lagerkvist S, Martin P, Pettersson F, Sonesson C, Waters S, Waters N. Ponten H, et al. Among authors: kullingsjo j. Eur J Pharmacol. 2010 Oct 10;644(1-3):88-95. doi: 10.1016/j.ejphar.2010.07.023. Epub 2010 Jul 24. Eur J Pharmacol. 2010. PMID: 20667452 Free article.

3

Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease.

Waters S, Sonesson C, Svensson P, Tedroff J, Carta M, Ljung E, Gunnergren J, Edling M, Svanberg B, Fagerberg A, Kullingsjö J, Hjorth S, Waters N. Waters S, et al. Among authors: kullingsjo j. J Pharmacol Exp Ther. 2020 Jul;374(1):113-125. doi: 10.1124/jpet.119.264226. Epub 2020 May 1. J Pharmacol Exp Ther. 2020. PMID: 32358046

4

In Vivo Systems Response Profiling and Multivariate Classification of CNS Active Compounds: A Structured Tool for CNS Drug Discovery.

Waters S, Svensson P, Kullingsjö J, Pontén H, Andreasson T, Sunesson Y, Ljung E, Sonesson C, Waters N. Waters S, et al. Among authors: kullingsjo j. ACS Chem Neurosci. 2017 Apr 19;8(4):785-797. doi: 10.1021/acschemneuro.6b00371. Epub 2017 Jan 9. ACS Chem Neurosci. 2017. PMID: 27997108 Free article.

5

Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease.

Esmaeilzadeh M, Kullingsjö J, Ullman H, Varrone A, Tedroff J. Esmaeilzadeh M, et al. Among authors: kullingsjo j. Clin Neuropharmacol. 2011 May-Jun;34(3):95-100. doi: 10.1097/WNF.0b013e31821c31d8. Clin Neuropharmacol. 2011. PMID: 21586914 Clinical Trial.

6

Automated phenotyping and advanced data mining exemplified in rats transgenic for Huntington's disease.

Urbach YK, Raber KA, Canneva F, Plank AC, Andreasson T, Ponten H, Kullingsjö J, Nguyen HP, Riess O, von Hörsten S. Urbach YK, et al. Among authors: kullingsjo j. J Neurosci Methods. 2014 Aug 30;234:38-53. doi: 10.1016/j.jneumeth.2014.06.017. Epub 2014 Jul 11. J Neurosci Methods. 2014. PMID: 25020253

7

Sustained administration of the antidepressant venlafaxine in rats: pharmacokinetic and pharmacodynamic findings.

Wikell C, Hjorth S, Apelqvist G, Kullingsjö J, Lundmark J, Bergqvist PB, Bengtsson F. Wikell C, et al. Among authors: kullingsjo j. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):448-55. doi: 10.1007/s002100100405. Naunyn Schmiedebergs Arch Pharmacol. 2001. PMID: 11330339

8

Effects on drug disposition, brain monoamines and behavior after chronic treatment with the antidepressant venlafaxine in rats with experimental hepatic encephalopathy.

Wikell C, Apelqvist G, Hjorth S, Kullingsjö J, Bergqvist PB, Bengtsson F. Wikell C, et al. Among authors: kullingsjo j. Eur Neuropsychopharmacol. 2002 Aug;12(4):327-36. doi: 10.1016/s0924-977x(02)00044-5. Eur Neuropsychopharmacol. 2002. PMID: 12126872

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

8 results

Search Page